PD-L1 Antibody – Mouse Monoclonal

Background: Each year, thousands of dogs are identified with cancer. Canine cancers bear many of the hallmarks of human cancers including tissue location, tumor progression, and response to chemotherapy and radiation. Unfortunately, canine lymphocyte populations are not as well defined as human lymphocytes, and reagents that target immune checkpoint pathways are not yet widely available for veterinary research. Interruption of the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway is an established and effective therapeutic strategy in human oncology and may be effective for treating canine cancers as well.

Choi JW et al. 2020 Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. PLoS One. 2020; 15(7): e0235518.

Small volumes of anti-PD-L1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS191624 is an antibody targeting PD-L1. Also known as Canine PD-L1 Monoclonal Antibody. Reactive in Canine. Host: Mouse.